Search
JNJ-42165279
go.drugbank.com/drugs/DB15173InvestigationalJnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).
Olomorasib
go.drugbank.com/drugs/DB21697InvestigationalOlomorasib is under investigation in clinical trial NCT06890598 (Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small … Olomorasib is a small molecule drug. The usage of the INN stem '-rasib' in the name indicates that Olomorasib is a Ras protein inhibitor.
SYNB1353
go.drugbank.com/drugs/DB17666InvestigationalIt is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983] … [A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria.
Zavacorilant
go.drugbank.com/drugs/DB21509InvestigationalZavacorilant is under investigation in clinical trial NCT04672512 (Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants). … Zavacorilant is a small molecule drug. The usage of the INN stem '-corilant' in the name indicates that Zavacorilant is a glucocorticoid receptor antagonist (non-steroidal).
Xiliertinib
go.drugbank.com/drugs/DB21453InvestigationalXiliertinib is under investigation in clinical trial NCT02601274 (Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor). Xiliertinib has a monoisotopic molecular weight of 442.21 Da. … Xiliertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Xiliertinib is a epidermal growth factor receptor (EGFR) inhibitor.
Paltimatrectinib
go.drugbank.com/drugs/DB21588InvestigationalPaltimatrectinib is under investigation in clinical trial NCT04901806 (Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors). … Paltimatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Paltimatrectinib is a tropomyosin receptor kinase (TRK) inhibitor.